Olwyn M.R. Westwood
St George's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Olwyn M.R. Westwood.
Clinical medicine insights. Arthritis and musculoskeletal disorders | 2008
Paul N. Nelson; Olwyn M.R. Westwood; Graham L. Freimanis; Denise A. Roden; Samir Sissaoui; Paul Rylance; Frank C. Hay
Epitope mapping allowed the location of antigenic determinants on a protein macromolecule to be identified. In particular, pepscan techniques that utilize a series of overlapping peptides, help detect key amino acid residues that are important in antibody recognition and binding. In a previous study, we employed 15-mer peptides spanning the entire length of IgG1Fc to ascertain successfully the target epitopes of isotypic/allotypic monoclonal reagents. As an extension to this work we have used these peptides to evaluate the location of epitope targets of five IgM rheumatoid factor antibodies (RFAbs). Overall, 2 antibodies, RFAb TS2 and TS1, detected a similar epitope within the CH3 domain (360-KNQVSLTCLVKGFYP-374), whilst 1 (RFAb SJ1) recognised an epitope in the CH2 domain (294-EQYNSTYRVVSVLTV-308). In contrast, 2 RFAbs, PRSJ2 and PRTS1 detected four and five epitopes respectively within the Fc region. RFAb PRSJ2 recognised epitopes detected by RFAB TS2 and TS1 but also further epitopes in the CH2 domain (256-TPEVTCVVVDVSHED-270) and CH3 domain (418-QQGNVFSCSVMHEAL-432). Similarly, RFAb PRTS1 detected all four epitopes plus a fifth in the CH3 domain (382-ESNGQPENNYKTTPP-396). In essence there was a consensus of target epitopes identified by these rheumatoid factor antibodies. Interestingly, two epitopes (256–270, CH2 domain and 360–374, CH3 domain) were novel in that they had not been identified in previous pepscan studies. The other epitopes recognised, either overlapped or were immediately adjacent to previous epitopes detected by poly/monoclonal rheumatoid factor antibodies. Molecular modelling (PCImdad) of IgG1Fc showed that all five epitopes were exposed and surface accessible for antibody interaction. In addition, a bioinformatics analysis of the Fc region using ExPASy was employed to identify key antigenic determinants. This ‘in silico’ approach may provide a means of determining key regions without the need to develop overlapping peptides spanning the entire length of a macromolecule.
Cytotechnology | 1993
Andrew Robinson; Mingyue He; Olwyn M.R. Westwood; Brian M. Austen
Two pathways operate to target newly-synthesised proteins to the endoplasmic reticulum. In one, the signal recognition particle attaches to the signal sequences of nascent chains on ribosomes and slows or stops translation until contact is made with the docking protein at the membrane. The second operates via molecular chaperons. The pathways converge at the level of a 43 kDa signal binding protein integrated into the membrane, where translocation through a proteinaceous pore is initiated. In the lumen, proteins fold and disulphide formation is catalysed by the enzyme protein disulphide isomerase. The heavy chain binding protein may attach to unassembled or unfolded proteins and prevent their exit from the ER to the Golgi. Cholecystokinin (CCK) treatment increases the biosynthesis and secretion of pancreatic proteins, increases the levels of PDI and the 43 kDa binding protein, and reduces levels of BiP. These proteins may be possible targets for genetic manipulation to improve processing of heterologous proteins from cultured mammalian cells.
Archive | 1993
Olwyn M.R. Westwood; Brian M. Austen
Candidate proteins of the endoplasmic reticulum (ER) membrane functional in the translocation of newly-synthesised proteins from the cytoplasm to the lumen have been identified using cross-linking to photoreactive truncated nascent polypeptides paused in the act of translocation. Proteins include SSRalpha, a glycoprotein of 34kDa Mr (Weidmann et al, 1987), which has one transmembrane region and is part of a heterotetrameric complex, while a glycoprotein of 36kDa, translocating chain-associated membrane protein (TRAM), is cross-linked in reconstituted proteoliposomes to a translocation intermediate with carbodiimide. TRAM is predicted to cross the membrane eight times (Gorlich et al., 1992).
Archive | 2000
Olwyn M.R. Westwood; Frank C. Hay
Rheumatology | 2006
Olwyn M.R. Westwood; Paul N. Nelson; Frank C. Hay
Archive | 1991
Brian M. Austen; Olwyn M.R. Westwood
Archive | 2008
Frank C. Hay; Olwyn M.R. Westwood
Archive | 2008
Frank C. Hay; Olwyn M.R. Westwood
Archive | 2008
Frank C. Hay; Olwyn M.R. Westwood
Biochemical Journal | 1990
Andrew Robinson; Olwyn M.R. Westwood; Brian M. Austen